Book contents
- Cambridge Handbook of Pain Medicine
- Cambridge Handbook of Pain Medicine
- Copyright page
- Contents
- Contributors
- Pain Handbook Introduction
- Part I Introduction to Pain: Pain Signaling Pathways
- Part II Common Categories of Pharmacologic Medications to Treat Chronic Pain
- Part III Chronic Pain Conditions Head and Neck
- Part IV Spine
- Part V Extremities
- Part VI Misc
- Chapter 26 Post-herpetic Neuralgia (PHN)
- Chapter 27 Complex Regional Pain Syndrome (CRPS)
- Chapter 28 Sickle Cell Disease
- Chapter 29 Breast Pain
- Chapter 30 Post-thoracotomy Pain
- Chapter 31 Multiple Sclerosis Pain
- Chapter 32 Cerebral Palsy
- Chapter 33 Myofascial Pain Syndrome
- Chapter 34 Post-stroke Pain
- Chapter 35 Chronic Abdominal Pain
- Chapter 36 Chronic Pelvic Pain
- Chapter 37 Postsurgical Nerve Entrapment
- Chapter 38 Cancer Pain
- Part VII Adjunctive Therapy
- Index
- References
Chapter 26 - Post-herpetic Neuralgia (PHN)
from Part VI - Misc
Published online by Cambridge University Press: 01 December 2023
- Cambridge Handbook of Pain Medicine
- Cambridge Handbook of Pain Medicine
- Copyright page
- Contents
- Contributors
- Pain Handbook Introduction
- Part I Introduction to Pain: Pain Signaling Pathways
- Part II Common Categories of Pharmacologic Medications to Treat Chronic Pain
- Part III Chronic Pain Conditions Head and Neck
- Part IV Spine
- Part V Extremities
- Part VI Misc
- Chapter 26 Post-herpetic Neuralgia (PHN)
- Chapter 27 Complex Regional Pain Syndrome (CRPS)
- Chapter 28 Sickle Cell Disease
- Chapter 29 Breast Pain
- Chapter 30 Post-thoracotomy Pain
- Chapter 31 Multiple Sclerosis Pain
- Chapter 32 Cerebral Palsy
- Chapter 33 Myofascial Pain Syndrome
- Chapter 34 Post-stroke Pain
- Chapter 35 Chronic Abdominal Pain
- Chapter 36 Chronic Pelvic Pain
- Chapter 37 Postsurgical Nerve Entrapment
- Chapter 38 Cancer Pain
- Part VII Adjunctive Therapy
- Index
- References
Summary
Post-herpetic neuralgia (PHN) is a common, painful reaction following herpes zoster (HZ) infection. There have been one million cases of HZ per year, with 20% resulting in PHN, which is the prevalent condition that significantly reduces the quality of life in affected individuals. There is increased nociception in dermatomal region following typical HZ rash. The strongest risk factor is increasing age, and the FDA recommends all people age >50 to get vaccinated as a prevention. First-line treatments include topical capsaicin, lidocaine, and pharmacological management with TCAs and Calcium channel a2d ligands. Myriad of other treatment options are available, many with conflicting evidence.
- Type
- Chapter
- Information
- Cambridge Handbook of Pain Medicine , pp. 213 - 219Publisher: Cambridge University PressPrint publication year: 2023